bluebird bio (BLUE)
(Real Time Quote from BATS)
$0.91 USD
0.00 (-0.27%)
Updated Apr 26, 2024 10:26 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Bluebird Bio (BLUE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.34 | $8.00 | $1.00 | 376.92% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Bluebird Bio comes to $4.34. The forecasts range from a low of $1.00 to a high of $8.00. The average price target represents an increase of 376.92% from the last closing price of $0.91.
Analyst Price Targets (11)
Broker Rating
Bluebird Bio currently has an average brokerage recommendation (ABR) of 2.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 2.57 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 28.57% and 7.14% of all recommendations. A month ago, Strong Buy made up 28.57%, while Buy represented 7.14%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 0 | 0 |
Hold | 7 | 7 | 7 | 7 | 7 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.57 | 2.57 | 2.57 | 2.62 | 2.62 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/26/2024 | Not Identified | Not Identified | Not Available | Moderate Buy |
3/19/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
3/8/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
1/9/2024 | William Blair | Sami Corwin | Hold | Hold |
12/12/2023 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
11/7/2023 | SVB Securities | Mani Foroohar | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.57 |
ABR (Last week) | 2.57 |
# of Recs in ABR | 14 |
Average Target Price | $4.34 |
LT Growth Rate | 38.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.47 |